HK1245675A1 - 多价人免疫缺陷病毒抗原结合分子及其用途 - Google Patents

多价人免疫缺陷病毒抗原结合分子及其用途 Download PDF

Info

Publication number
HK1245675A1
HK1245675A1 HK18105481.5A HK18105481A HK1245675A1 HK 1245675 A1 HK1245675 A1 HK 1245675A1 HK 18105481 A HK18105481 A HK 18105481A HK 1245675 A1 HK1245675 A1 HK 1245675A1
Authority
HK
Hong Kong
Prior art keywords
binding molecules
multimeric
immunodeficiency virus
human immunodeficiency
antigen binding
Prior art date
Application number
HK18105481.5A
Other languages
English (en)
Chinese (zh)
Inventor
Bruce Keyt
Dan T. Stinchcomb
Ole A. Olsen
Original Assignee
Igm Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences, Inc. filed Critical Igm Biosciences, Inc.
Publication of HK1245675A1 publication Critical patent/HK1245675A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18105481.5A 2015-04-17 2016-04-15 多价人免疫缺陷病毒抗原结合分子及其用途 HK1245675A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149460P 2015-04-17 2015-04-17
US201562149460P 2015-04-17
PCT/US2016/027979 WO2016168758A1 (en) 2015-04-17 2016-04-15 Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
HK1245675A1 true HK1245675A1 (zh) 2018-08-31

Family

ID=57126939

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105481.5A HK1245675A1 (zh) 2015-04-17 2016-04-15 多价人免疫缺陷病毒抗原结合分子及其用途

Country Status (8)

Country Link
US (2) US10570191B2 (https=)
EP (1) EP3283112A4 (https=)
JP (1) JP6811723B2 (https=)
CN (1) CN107847591B (https=)
AU (1) AU2016249404B2 (https=)
CA (1) CA2983034A1 (https=)
HK (1) HK1245675A1 (https=)
WO (1) WO2016168758A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｐｄ−ｌ１抗体
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
JP7009517B2 (ja) * 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
JP2021507717A (ja) * 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
EP3794027A4 (en) * 2018-05-18 2022-02-09 MacroGenics, Inc. OPTIMIZED GP41 BINDING MOLECULES AND THEIR USES
HRP20250618T1 (hr) 2018-07-03 2025-07-18 Gilead Sciences, Inc. Protutijela koja ciljaju na hiv gp120 i postupci za uporabu
EP3830108A4 (en) * 2018-07-27 2022-08-10 International AIDS Vaccine Initiative GENETIC ANTIBODIES AGAINST HIV-ENV
US20220048988A1 (en) * 2018-09-13 2022-02-17 Children's National Medical Center Cells expressing antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
CN113166235A (zh) * 2018-11-22 2021-07-23 富士瑞必欧株式会社 抗体偶联物
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
CN114641488B (zh) * 2019-07-08 2026-03-20 加州理工学院 具有降低的多反应性的抗hiv疫苗抗体
MX2022001934A (es) 2019-08-15 2022-03-11 Igm Biosciences Inc Moleculas de union multimericas inmunoestimuladoras.
EP4041757A4 (en) * 2019-09-26 2024-04-17 Regents of the University of Minnesota VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
US12195524B2 (en) * 2020-08-25 2025-01-14 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
CN116348136A (zh) * 2020-08-27 2023-06-27 希力德株式会社 新型冠状病毒重组刺突蛋白、编码该重组刺突蛋白的多核苷酸、包含多核苷酸的载体以及包含载体的用于预防或治疗冠状病毒感染的疫苗
CN113461811A (zh) * 2021-06-30 2021-10-01 复旦大学 一种双特异性抗hiv-1抗体
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
WO2025178915A1 (en) * 2024-02-23 2025-08-28 Icahn School Of Medicine At Mount Sinai Multivalent protein complexes und uses thereof
CN121537523B (zh) * 2026-01-19 2026-04-21 武汉睿欣和生物科技有限公司 一种用于胃蛋白酶原i检测的pgi单克隆抗体组合及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JP3463143B2 (ja) * 1995-12-18 2003-11-05 秀親 岡田 糖鎖認識抗体及びｈｉｖ感染症治療剤
TW505656B (en) 1995-12-18 2002-10-11 Otsuka Pharma Co Ltd Sugar-chain-recognizing antibodies and pharmaceutical composition for HIV infectious diseases
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19622088A1 (de) * 1996-05-31 1997-12-04 Boehringer Mannheim Gmbh Anti-HIV-Antikörper als Kontrollproben
AU740918B2 (en) * 1997-01-10 2001-11-15 Plantibodies Corporation Novel epithelial tissue targeting agent
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
CN1665842B (zh) * 2002-07-01 2011-09-28 冈田秀亲 诱导HIV感染细胞凋亡的人IgM抗体和用于HIV感染的药物
CA2520381A1 (en) * 2003-03-26 2004-10-14 Sudhir Paul Proteolytic and covalent antibodies
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US7513893B2 (en) * 2004-03-12 2009-04-07 Abraham Ebbie Soroudi Device and method for treatment of eyelid diseases
BRPI0514259A (pt) * 2004-08-11 2008-06-03 Trubion Pharmaceuticals Inc proteìna de fusão de domìnio de ligação
US20080038280A1 (en) 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
CN101098889A (zh) 2004-11-05 2008-01-02 盘林京有限公司 抗体导致的细胞膜损伤
AU2006245734C1 (en) * 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
PL2112158T3 (pl) * 2007-04-20 2012-03-30 Hoffmann La Roche Wykrywanie pierwotnych infekcji wywołanych patogenami
JP2012503771A (ja) * 2008-09-25 2012-02-09 デューク ユニバーシティー 抗体および抗体−ｈｉｖビリオン複合体を検出する方法
CA2767063A1 (en) * 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
AU2010298025B2 (en) * 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
AU2011215684A1 (en) * 2010-02-12 2012-08-30 Research Corporation Technologies Multimeric proteins comprising immunoglobulin constant domains
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
JP6205363B2 (ja) * 2011-09-26 2017-09-27 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
BR112014010823B1 (pt) 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2013110790A1 (en) * 2012-01-26 2013-08-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccine compositions for hiv prevention and treatment
TWI606064B (zh) 2012-02-08 2017-11-21 Ｉｇｍ生物科技公司 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
EP2828294A1 (en) 2012-03-23 2015-01-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
CN104684928A (zh) * 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
US20150216973A1 (en) * 2012-08-08 2015-08-06 Network Immunology Inc.. Method for the induction of an immune response
JP2014124186A (ja) * 2012-12-26 2014-07-07 Industrial Technology Research Institute 多価抗体フラグメントおよびその三量体化複合体
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
SG10201806025TA (en) 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2019530640A (ja) 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
AU2019224136A1 (en) 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof

Also Published As

Publication number Publication date
JP6811723B2 (ja) 2021-01-13
CA2983034A1 (en) 2016-10-20
AU2016249404B2 (en) 2021-01-21
EP3283112A1 (en) 2018-02-21
US11192941B2 (en) 2021-12-07
CN107847591A (zh) 2018-03-27
US10570191B2 (en) 2020-02-25
WO2016168758A1 (en) 2016-10-20
AU2016249404A1 (en) 2017-11-23
US20180118816A1 (en) 2018-05-03
CN107847591B (zh) 2023-07-28
EP3283112A4 (en) 2018-12-05
US20200377577A1 (en) 2020-12-03
JP2018512863A (ja) 2018-05-24

Similar Documents

Publication Publication Date Title
HK1245675A1 (zh) 多价人免疫缺陷病毒抗原结合分子及其用途
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1123719T1 (el) Πρωτεϊνες συντηξης θραυσματων ανθρωπινων πρωτεϊνων για τη δημιουργια τακτικα πολυμερισμενων συνθεσεων fc ανοσοσφαιρινων με ενισχυμενη δεσμευση συμπληρωματος
EP4613776A3 (en) Multimeric il-15-based molecules
EP3378871A4 (en) PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF
HK1252666A1 (zh) 针对cd40的抗体
EP4321171A3 (en) Sirp alpha-antibody fusion proteins
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
PH12017500892A1 (en) Antigen binding molecules comprising a tnf family ligand trimer
EP3274051A4 (en) Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016207273A3 (en) Multispecific antigen binding proteins
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
WO2015109124A3 (en) Immunomodulatory agents
WO2015197598A3 (en) Multispecific antigen binding proteins
HK1252791A1 (zh) 具有经修饰的j链的结合分子
HK1254951A1 (zh) Pd1和/或lag3结合剂
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
GEAP202014811A (en) Ctla4 binders
MA46419A (fr) Molécule de liaison aux antigènes multispécifique présentant de meilleures caractéristiques d'internalisation
WO2014059442A8 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
MX2021000387A (es) Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2